The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Official Title: Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2
Study ID: NCT01836575
Brief Summary: Optimal management of patients with advanced NSCLC and with PS 2 remains controversial and underrepresented in clinical trials, typically accounting for 5 to 10% of enrolled patients. Patient PS 2 proportion in population-based studies is considerably higher than that included in clinical trials. Management of patients with PS of 2 in clinical practice is empirical and inconsistent. Patients have median overall survival of 3 to 5 months in randomized trials, and treatment options include best supportive care, single-agent and combination chemotherapy. Retrospective studies have suggested that patients PS 2 may benefit from first-line chemotherapy in terms of symptom improvement and overall survival. In many of these studies, single-agent chemotherapy was compared with best supportive care alone. Data on the role of cisplatin-based combinations for patients with PS 2 is more scant, with one study questioning its benefit, and another interrupting accrual because of undue toxicity. With regards to carboplatin, the Cancer and Leukemia Group B (CALGB) study 9730 compared paclitaxel plus carboplatin versus paclitaxel alone in a subgroup of 107 patients with PS 2; the median overall survival was significantly longer in group treated with combination chemotherapy (4.7 versus 2.4 months). Combination chemotherapy with carboplatin and paclitaxel also produced a statistically significantly higher incidence of severe hematological and non-hematological toxicities. On the basis of aforementioned results, a recent European panel stated that carboplatin-based or low-dose cisplatin-based doublets might represent alternative options to single-agent chemoterapy in patients PS 2. Outside clinical trials, single-agent chemotherapy with a 3rd generation agent remains valid option for patients PS2. Results demonstrate that pemetrexed is an agent with established single-agent activity in NSCLC, and suggest it is a potential candidate for combinations with platinum and other agents currently utilized for patients with advanced NSCLC. Favorable toxicity profile of pemetrexed suggests that this agent is an ideal candidate for single agent testing and in combination among patients with PS 2. Substantial doubt remains in the comparative benefit from monotherapy versus combination. Starting dose and schedule of pemetrexed were set for this study based on its current labeling in the 2nd line treatment of metastatic NSCLC and 1st line treatment of malignant pleural mesothelioma.
Detailed Description: This is a Phase III, open label, randomized study to enroll 228 patients with advanced in a 1:1 ratio at the time of registration. Patients in Arm A will receive pemetrexed, 500 mg/m2, with appropriate vitamin supplementation; patients in Arm B will receive the same dose and schedule of pemetrexed as in Arm A, in combination with carboplatin, AUC of 5. For the purpose of the study, treatment (Arm A or Arm B) will consist of up to four cycles of therapy (repeated every 21 days). Primary endpoint of the study is overall survival; secondary endpoints include toxicity, response rate, and progression-free survival. At the time of analysis, patients will be stratified according to age (≥ 70 versus \< 70 years), disease stage (IIIB versus IV), site, and weight loss (≥ 5 Kg versus \< 5 Kg). The dose of carboplatin will be determined according to the formula developed by Calvert et al., which is shown in equation \[1\] below and uses the estimated creatinine clearance according to the method of Cockcroft and Gault for estimation of the glomerular filtration rate (GFR) (equation \[2\] below): 1. Dose of carboplatin (mg) = Target AUC x (GFR + 25) 2. GFR = (140 - Age) x Weight/(72 x serum creatinine) (multiply by 0.85 in women) Sample Size and Expected Accrual In the CALGB 9730 study of advanced NSCLC, first-line treatment with paclitaxel plus carboplatin resulted in a median overall survival of 4.7 months among patients with a performance status of 2. In the ECOG 1594 study, the median overall survival of patients with a performance status of 2 who were treated with platinum-based doublets was 4.1 months. Approximately 208 eligible patients are needed to provide 80% power to detect a difference between the two treatment arms with a two-sided type I error of 0.05, assuming that pemetrexed plus carboplatin will result in a median survival of at least 4.3 months, and pemetrexed alone 2.9 months. An additional 20 patients will be accrued to account for an early dropout rate of 10%, for a total of 228 patients. It is anticipated that the accrual time will be approximately 22 months and patients will be followed for 1 year after completion of treatment; therefore, 2 years and 10 months will be needed to complete the study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Instituto do Câncer do Ceará - ICC, Fortaleza, Ceará, Brazil
Hospital Lifecenter, Belo Horizonte, Minas Gerais, Brazil
Hospital Caridade de Ijuí - CACON, Ijuí, RS, Brazil
Hospital São Lucas, Porto Alegre, RS, Brazil
Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Santa Catarina, Brazil
Hospital Amaral Carvalho, Jaú, São Paulo, Brazil
INCA, Rio de Janeiro, , Brazil
Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo, , Brazil
Name: Carlos G Ferreira, PhD
Affiliation: National Cancer Institute, France
Role: PRINCIPAL_INVESTIGATOR
Name: Rogerio Lilenbaum, MD
Affiliation: The Mount Sinai Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Carlos Henrique E Barrios, MD
Affiliation: Pontifícia Universidade Católica do RS
Role: PRINCIPAL_INVESTIGATOR
Name: Carlos Augusto M. Beato, MD
Affiliation: Hospital Amaral Carvalho
Role: PRINCIPAL_INVESTIGATOR
Name: José Rodrigues, MD
Affiliation: Instituto do Câncer Arnaldo Vieira Carvalho - ICAVC
Role: PRINCIPAL_INVESTIGATOR
Name: Yeni Neron, MD
Affiliation: Centro de Pesquisas Oncológicas - CEPON
Role: PRINCIPAL_INVESTIGATOR
Name: André Murad, PhD
Affiliation: Lifecenter Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Ronaldo A Ribeiro, PhD
Affiliation: Instituto do Câncer do Ceará - ICC
Role: PRINCIPAL_INVESTIGATOR
Name: Fábio Franke, MD
Affiliation: Hospital de Caridade de Ijuí - CACON
Role: PRINCIPAL_INVESTIGATOR
Name: Mauro Zukin, MD
Affiliation: National Cancer Institute, France
Role: PRINCIPAL_INVESTIGATOR